Responsive and activable nanomedicines for remodeling the tumor microenvironment

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• The tumor microenvironment (TME) plays a critical role in tumor progression and metastasis.
• Targeting the relatively stable TME offers a promising therapeutic strategy compared to targeting rapidly mutating tumor cells.
• Multifunctional nanomedicines hold potential for anti-tumor therapy by modulating the TME.

Purpose of the Study:

• To develop protocols for constructing responsive and activable nanomedicines.
• To investigate the regulation of tumor-associated platelets and pancreatic stellate cells (PSCs) within the TME.
• To enhance drug delivery and therapeutic efficacy of chemotherapeutics by manipulating the TME.

Main Methods:

• Construction of responsive and activable nanomedicines.
• Characterization of nanoformulations for TME regulation.
• Application of nanomedicines to modulate tumor-associated platelets and PSCs.

Main Results:

• Protocols for nanomedicine preparation were established (~10 h for platelet regulation, ~16 h for PSC regulation).
• Nanoparticles effectively regulate key TME components, including tumor-associated platelets and PSCs.
• Demonstrated potential for enhanced drug delivery, tumor penetration, and chemotherapeutic efficacy.

Conclusions:

• Developed nanomedicines can regulate the TME by targeting major cellular players.
• These nanoformulations offer a strategy to overcome physiological barriers for improved anti-tumor therapy.
• The approach is adaptable for regulating other TME components to achieve synergistic or additive anti-tumor effects.